10x Genomics (NASDAQ:TXG - Get Free Report) is set to release its earnings data after the market closes on Tuesday, October 29th. Analysts expect 10x Genomics to post earnings of ($0.34) per share for the quarter. 10x Genomics has set its FY 2024 guidance at EPS.Persons that wish to listen to the company's earnings conference call can do so using this link.
10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.32) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.15. The firm had revenue of $153.10 million for the quarter, compared to analyst estimates of $150.90 million. 10x Genomics had a negative net margin of 37.90% and a negative return on equity of 28.23%. On average, analysts expect 10x Genomics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of TXG opened at $15.37 on Tuesday. The firm has a market capitalization of $1.85 billion, a PE ratio of -7.61 and a beta of 1.85. 10x Genomics has a 1-year low of $14.02 and a 1-year high of $57.90. The company's fifty day moving average price is $21.00 and its 200-day moving average price is $22.39.
A number of brokerages have recently weighed in on TXG. Barclays dropped their price objective on shares of 10x Genomics from $24.00 to $21.00 and set an "overweight" rating on the stock in a report on Tuesday, October 15th. The Goldman Sachs Group lowered their price target on shares of 10x Genomics from $26.00 to $16.00 and set a "sell" rating on the stock in a report on Tuesday, July 9th. Stifel Nicolaus lowered their price target on shares of 10x Genomics from $53.00 to $25.00 and set a "buy" rating on the stock in a report on Tuesday, July 16th. Canaccord Genuity Group lowered their price target on shares of 10x Genomics from $32.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, October 10th. Finally, Morgan Stanley lowered their price target on shares of 10x Genomics from $50.00 to $46.00 and set an "overweight" rating on the stock in a report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, 10x Genomics presently has an average rating of "Moderate Buy" and an average price target of $30.60.
Get Our Latest Stock Analysis on TXG
In related news, insider Benjamin J. Hindson sold 4,351 shares of the company's stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total transaction of $98,028.03. Following the completion of the transaction, the insider now owns 345,704 shares in the company, valued at $7,788,711.12. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other 10x Genomics news, insider Benjamin J. Hindson sold 4,351 shares of the stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total value of $98,028.03. Following the completion of the sale, the insider now owns 345,704 shares in the company, valued at approximately $7,788,711.12. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Justin J. Mcanear sold 2,961 shares of the stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total transaction of $66,711.33. Following the completion of the sale, the chief financial officer now owns 143,242 shares of the company's stock, valued at approximately $3,227,242.26. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 14,061 shares of company stock worth $316,794 in the last 90 days. Insiders own 10.03% of the company's stock.
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider 10x Genomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.
While 10x Genomics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.